Previously we reported our prospective phase II study in this journal [1]. The follow up time increased 26months at this time from the previous analysis. The median follow-up time was 64months (range; 50–85months) for surviving patients. The recurrence of the esophageal cancer increased by three patients to the total of 31 patients, who had a first recurrence in liver at 25months, primary tumor at 37months, and right recurrent laryngeal nerve lymph node within radiation field at 39months after the onset of treatment, respectively.
http://ift.tt/2pKVBSW
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου